Millendo Therapeutics, Inc.

Millendo Therapeutics, Inc. is a biotechnology firm focused on developing innovative oncology therapeutics. The company aims to address unmet medical needs in cancer treatment, leveraging advanced drug technologies to improve patient outcomes. Millendo Therapeutics, Inc.

specializes in biopharmaceutical development, particularly for oncology therapies. Founded in 2012, the company is headquartered in Ann Arbor, Michigan, US. Gary Hammer, a notable figure in the biotech sector, is one of the founders. The firm has undergone a significant transformation, including a reverse merger with OvaScience, Inc.

in August 2018, which has enhanced its operational capabilities. Millendo has successfully raised USD 47. 70 mn through a SERIES B funding round led by New Enterprise Associates, which marks its total amount raised at USD 47. 70 mn, contributing to a current company valuation of USD 101.

32 mn. Millendo Therapeutics focuses on developing first-in-class oral drug therapeutics aimed at treating various forms of cancer. Their flagship product, Amezalpat (TPST-1120), is currently undergoing pivotal trials for first-line hepatocellular carcinoma (HCC) in China, targeting specific cancer pathways to enhance treatment efficacy and reduce adverse effects. The company markets its therapeutic offerings primarily in North America and Asia, particularly in China, where it is advancing clinical trials towards regulatory approval.

Millendo Therapeutics generates revenue through strategic partnerships and funding for clinical trials, which are vital for the ongoing development of its therapeutic products. Collaborations with pharmaceutical companies are intended to facilitate joint development of their innovative treatments, potentially leading to shared revenues post-commercialization. Once Amezalpat reaches the market, the company will also engage in direct-to-consumer sales through healthcare providers, with pricing strategies aligned with clinical trial outcomes and market evaluations. Looking ahead, Millendo Therapeutics plans to expand its product lineup and geographical presence.

The focus includes advancing Amezalpat towards regulatory approval and exploring additional oncology therapies. The company intends to leverage its recent funding of USD 47. 70 mn from the SERIES B round, led by New Enterprise Associates, to support these initiatives. Additionally, Millendo aims to solidify its market position in China and other targeted regions by the next few years, enhancing its ability to deliver innovative cancer therapies.